Skip to main content

Table 2 Therapeutic effects, adverse events and regimen changes in the four patient groups

From: Impact of renal function-based anti-tuberculosis drug dosage adjustment on efficacy and safety outcomes in pulmonary tuberculosis complicated with chronic kidney disease

 

Total

Non-CKD

CKD group

Subtotal of CKD groups

P value*

Mild CKD

Moderate CKD

Severe CKD

n = 241

n = 87

n = 93

n = 43

n = 18

n = 154

Therapeutic effects

 In-hospital TB-related death

14 (5.8%)

3 (3.4%)

5 (5.4%)

5 (11.6%)

1 (5.6%)

11 (7.1%)

0.310

 Sputum culture conversion at 2 months†

174 (78.0%)

67 (77.9%)

66 (76.7%)

28 (77.8%)

13 (86.7%)

107 (78.1%)

0.864

Any adverse events

60 (24.9%)

18 (20.7%)

19 (20.4%)

15 (34.9%)

8 (44.4%)

42 (27.3%)

0.051

No adverse event

181 (75.1%)

69 (79.3%)

74 (79.6%)

28 (65.1%)

10 (55.6%)

112 (72.7%)

–

Drug-induced hepatitis

28 (11.6%)

6 (6.9%)

12 (12.9%)

8 (18.6%)

2 (11.1%)

22 (14.3%)

0.252

Cutaneous reaction

19 (7.9%)

8 (9.2%)

6 (6.5%)

3 (7.0%)

2 (11.1%)

11 (7.1%)

0.855

Drug-induced nephropathy

7 (2.9%)

0 (0%)

0 (0%)

5 (11.6%)

2 (11.1%)

7 (4.5%)

N/A‡

Gastrointestinal disorder

6 (2.5%)

1 (1.1%)

2 (2.2%)

1 (2.3%)

2 (11.1%)

5 (3.2%)

N/A

Gout attack

5 (2.1%)

4 (4.6%)

0 (0%)

0 (0%)

1 (5.6%)

1 (0.6%)

N/A

Haematotoxicity

3 (1.2%)

0 (0%)

2 (2.2%)

0 (0%)

1 (5.6%)

3 (1.9%)

N/A

Peripheral neuropathy

1 (0.4%)

1 (1.1%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

N/A

Anaphylaxis

1 (0.4%)

0 (0%)

0 (0%)

1 (2.3%)

0 (0%)

1 (0.6%)

N/A

Regimen change

28 (11.6%)

3 (3.4%)

10 (10.8%)

9 (20.9%)

6 (33.3%)

25 (16.2%)

< 0.001

  1. There was some overlap
  2. *Chi-square test was used to compare for each parameter
  3. ‡N/A, chi-square test was not applicable because of insufficient expected values in some cells
  4. §The number of patients alive at 2 months was 223 (86 patients in the non-CKD group, 86 in the mild CKD group, 36 in the moderate CKD group and 15 in the severe CKD group)
  5. CKD chronic kidney disease